4,326 件 ・ 関連度順
概要と使いどころ
Plans and drives cross-functional programs to delivery — scope, sequencing, dependencies, status, risk, and the escalations that keep work moving. Use this to run a multi-team initiative, recover a program that is slipping, build a delivery plan with dependencies, structure status reporting, or diagnose why cross-team work keeps missing dates.
日本語の概要は準備中です。原文の説明を表示しています。
Upgrades an existing interface to a higher standard without rebuilding it — auditing what is there, identifying what reads as generic or unfinished, and sequencing changes by impact. Use this when a product works but looks dated or default, when a redesign is being considered, when deciding whether to restyle or rebuild, or when a screen needs to look substantially better with limited effort.
日本語の概要は準備中です。原文の説明を表示しています。
Governs the portfolio of work — intake, prioritization, stage gates, resource contention, and stopping things. Use this to set up intake and prioritization, run a stage gate, decide between competing initiatives, resolve resource contention across projects, or work out why everything is in flight and nothing is finishing.
日本語の概要は準備中です。原文の説明を表示しています。
Defines and manages service levels — setting targets that reflect what customers need, measuring honestly, and handling breaches. Use this to write or negotiate an SLA, decide what to measure and at what threshold, respond to a missed service level, or work out why a service that meets its targets still has unhappy customers.
日本語の概要は準備中です。原文の説明を表示しています。
Identifies, assesses, and tracks organizational risk — building and maintaining a risk register, scoring exposure, assigning owners and treatments, and preparing for audit. Use this to stand up a risk program, assess the risk in a decision or initiative, prepare for a certification or audit, decide whether a risk should be accepted, mitigated, transferred, or avoided, or report risk posture to leadership.
日本語の概要は準備中です。原文の説明を表示しています。
Decides where capital and attention go across business lines, products, and markets — what to fund, hold, harvest, or exit, and on what evidence. Use this to allocate budget across businesses, evaluate whether a product line should continue, decide whether to exit one, structure a portfolio review, or when several initiatives compete for the same limited investment.
日本語の概要は準備中です。原文の説明を表示しています。
Governs models and AI systems in production — intended use, evaluation, monitoring, human oversight, documentation, and the decision to deploy or retire. Use this before deploying a model or AI feature, when defining evaluation criteria, when a model's behavior has drifted, when assessing AI risk or regulatory exposure, or when deciding whether an AI system is fit for a consequential decision.
日本語の概要は準備中です。原文の説明を表示しています。
Pressure-tests a decision, plan, or idea before it is committed to — surfacing the assumption it rests on, the case against it, and what would have to be true for it to work. Use this when weighing options, when a plan needs challenging before commitment, when you have already decided and want a genuine gut check, when processing meeting notes into decisions, or when competing initiatives need ranking. Distinct from `chief-executive`, which owns direction; this one interrogates a specific decision.
日本語の概要は準備中です。原文の説明を表示しています。
Designs and runs the support function — channels, queues, routing, staffing, service levels, quality, and the metrics that show whether it is working. Use this to set up or fix support operations, choose channels, size a team, set or renegotiate service levels, reduce cost per contact, diagnose long queues or poor quality, or decide what to automate.
日本語の概要は準備中です。原文の説明を表示しています。
Finds the single constraint currently limiting a business's growth and the highest-leverage moves against it, rather than producing a list of everything that could be improved. Use this when growth has stalled or slowed, when deciding where to spend limited time or budget, when revenue rises but profit does not, when prioritizing growth initiatives, or when a business feels busy without compounding.
日本語の概要は準備中です。原文の説明を表示しています。
Structures partnerships that change what the business can do — technology integrations, channel and reseller arrangements, joint ventures, and OEM relationships. Use this to evaluate or structure a strategic partnership, decide between partnering and building, negotiate commercial terms of an alliance, or diagnose a partnership that is signed but not producing. For audience-borrowing partnerships, use `marketing:partnership-marketing`.
日本語の概要は準備中です。原文の説明を表示しています。
Apply when designing commands, lifecycle steps, or processing loops that run amid crashes, restarts, and retries. Converge to the same end state regardless of partial prior runs.
日本語の概要は準備中です。原文の説明を表示しています。
Generate Baujat plots for heterogeneity analysis. Identify studies that contribute most to the overall meta-analysis results and heterogeneity, helping discover potential outlier studies. Input meta-analysis data CSV, output Baujat plot PNG and contribution data CSV.
日本語の概要は準備中です。原文の説明を表示しています。
This skill is applicable when using LaminDB. LaminDB is an open-source data framework for biology that makes data queryable, traceable, reproducible, and FAIR-compliant. It is suitable for managing biological datasets (scRNA-seq, spatial transcriptomics, flow cytometry, etc.), tracking computational workflows, curating and validating data with biological ontologies, building data lakes, or ensuring data lineage and reproducibility in biological research. It covers data management, annotation, ontologies (genes, cell types, diseases, tissues), schema validation, integration with workflow managers (Nextflow, Snakemake) and MLOps platforms (W&B, MLflow), and deployment strategies.
日本語の概要は準備中です。原文の説明を表示しています。
Process CRISPR screening data to identify essential genes and hit candidates. Performs quality control, statistical analysis (RRA), and hit calling for pooled CRISPR screens including viability screens and drug resistance/sensitivity studies.
日本語の概要は準備中です。原文の説明を表示しています。
1. Confirm the user objective, required inputs, and non-negotiable constraints before doing detailed work. 2. Validate that the request matches the documented scope and stop early if the task would require unsupported as.
日本語の概要は準備中です。原文の説明を表示しています。
Designs QTL colocalization studies that connect eQTL, pQTL, sQTL, or related molecular QTL signals with GWAS loci. Always use this skill whenever a user wants to plan, scope, or structure a locus-level study asking whether a GWAS association and a molecular QTL association may reflect the same underlying causal signal. Covers locus definition, QTL/GWAS source architecture, ancestry and LD alignment, single-locus vs multi-locus strategy, candidate-gene prioritization, optional fine-mapping, linked MR/SMR follow-up, and functional annotation. Always output four workload configurations (Lite / Standard / Advanced / Publication+) with a recommended primary plan, stepwise workflow, method rationale, evidence hierarchy, figure plan, minimal executable version, and strictly verified literature guidance with no fabricated references. Never equate colocalization with causality proof, mediation proof, or automatic target validation. Always include the mandatory Dataset Disclaimer immediately before any workflow section that mentions datasets, repositories, consortia, or public resources.
日本語の概要は準備中です。原文の説明を表示しています。
Generates complete dual-disease shared-transcriptome biomarker and hub-gene research designs from a user-provided disease pair and shared-biology direction. Always use this skill whenever a user wants to design, plan, or build a non-oncology two-disease transcriptome study centered on per-disease differential expression, shared-signal intersection or concordance, PPI-based hub-gene prioritization, diagnostic evaluation across both diseases, immune infiltration context, pathway interpretation, and optional orthogonal validation. Covers five study patterns (shared-DEG-first workflow, hub-gene-first shared-biomarker workflow, hybrid shared-biomarker compression workflow, immune-context shared-biomarker workflow, orthogonal validation workflow) and always outputs four workload configs (Lite / Standard / Advanced / Publication+) with recommended primary plan, step-by-step workflow, figure plan, validation strategy, minimal executable version, publication upgrade path...
日本語の概要は準備中です。原文の説明を表示しています。
Designs a realistic, execution-aware biomedical study version under explicit constraints of samples, time, budget, data access, lab capacity, team skill, and validation resources. Always use this skill when the user has a real study idea, a candidate route, or a partially framed project but cannot assume ideal conditions. If critical feasibility inputs are missing, first clarify what resources are currently available, what resources may be obtainable, and what resources are realistically unavailable. Do not invent access, capabilities, collaborations, or validation resources. Focus first on feasibility-constrained study framing, route narrowing, dependency control, and minimum viable study design.
日本語の概要は準備中です。原文の説明を表示しています。
Generates complete tumor immune-infiltration-guided bulk-transcriptome diagnostic biomarker and machine-learning research designs from a user-provided cancer type and study direction. Always use this skill whenever a user wants to design, plan, or build a tumor bioinformatics study centered on differential expression, immune infiltration estimation, immune-linked module discovery, consensus feature selection, diagnostic modeling, nomogram construction, clinical association, and optional prognostic extension or validation. Covers five study patterns (immune-cell-first diagnostic workflow, immune-module-to-biomarker workflow, consensus-ML biomarker workflow, diagnostic-plus-prognostic hybrid workflow, translational validation workflow) and always outputs four workload configs (Lite / Standard / Advanced / Publication+) with recommended primary plan, step-by-step workflow, figure plan, validation strategy, minimal executable version, publication upgrade path, reference literature pack, and self-critical risk review.
日本語の概要は準備中です。原文の説明を表示しています。
Generates complete conventional oncology bulk-transcriptome biomarker and hub-gene research designs from a user-provided cancer type and study direction. Always use this skill whenever a user wants to design, plan, or build a tumor bioinformatics study centered on differential expression, prognostic filtering or risk modeling, PPI-based hub-gene prioritization, diagnostic/prognostic evaluation, clinical association, immune infiltration context, methylation context, and optional tissue or cell validation. Covers five study patterns (signature-first prognostic workflow, hub-gene-first biomarker workflow, hybrid signature-to-hub workflow, immune-context biomarker workflow, translational validation workflow) and always outputs four workload configs (Lite / Standard / Advanced / Publication+) with recommended primary plan, step-by-step workflow, figure plan, validation strategy, minimal executable version, publication upgrade path...
日本語の概要は準備中です。原文の説明を表示しています。
Reverse-engineers the methods section of a biomedical paper into a structured, reproducible workflow. Use this skill when a user wants to understand how a study was actually executed, extract data sources, inclusion/exclusion logic, preprocessing, analytical sequence, software/tools, validation path, and critical parameters, or build a replication checklist from a paper, abstract, DOI, PMID, title, screenshot, or partial methods text. Do not treat this as generic summarization. Focus on reconstructing the operational method pipeline, surfacing missing reproducibility details, and distinguishing explicitly reported steps from inferred or unresolved ones. Never fabricate references, methods details, identifiers, software versions, parameters, datasets, or validation steps.
日本語の概要は準備中です。原文の説明を表示しています。
Reads a paper figure by figure before re-integrating the full narrative, so the user can identify the core findings quickly and check whether each visual actually supports the authors' main claims. Always separate figure content, figure-linked claim, evidentiary strength, and unsupported interpretation. Never fabricate references, PMIDs, DOIs, figure content, panel labels, result values, or study details that were not actually provided.
日本語の概要は準備中です。原文の説明を表示しています。
Use when building a weighted gene co-expression network from a bulk expression matrix and a sample group file, filtering variable genes by MAD, identifying co-expression modules with WGCNA, correlating modules with traits, and exporting module-level plots and gene tables. NOT for single-cell RNA-seq, differential expression testing, methylation analysis, or datasets that are too small for WGCNA after quality control.
日本語の概要は準備中です。原文の説明を表示しています。